As per Intent Market Research, the Genetic Testing Market was valued at USD 16.5 billion in 2024-e and will surpass USD 44.2 billion by 2030; growing at a CAGR of 15.2% during 2025 - 2030.
The genetic testing market is experiencing robust growth, driven by technological advancements and an increasing demand for personalized medicine. With applications in a wide range of fields such as disease diagnosis, prenatal screening, and pharmacogenomics, genetic testing is becoming an integral tool in clinical and research settings. The market is categorized into product types, technologies, applications, and end-user industries, with each segment witnessing specific trends that are shaping the future of genetic testing. Notably, the increasing affordability of genetic testing services and advancements in next-generation sequencing (NGS) technology have propelled the adoption of genetic testing across healthcare and research institutions globally.
Direct-to-Consumer Genetic Testing Segment Is Fastest Growing Owing to Increased Consumer Awareness
Direct-to-consumer (DTC) genetic testing has emerged as the fastest-growing segment within the genetic testing market. The appeal lies in its accessibility, as consumers can directly purchase testing kits without the need for a healthcare provider's involvement. The growing awareness about genetic health, along with increased consumer interest in ancestry and health risks, has led to a surge in demand for DTC genetic testing services. Companies like 23andMe and Ancestry.com have become household names, offering a range of genetic testing services that include health predispositions, ancestry tracing, and wellness insights. This ease of access and the increasing desire for personal health management are expected to further fuel growth in this segment.
Next-Generation Sequencing (NGS) Technology Is Leading the Way in Advancements
Next-generation sequencing (NGS) technology is currently the most prominent technology in the genetic testing market. It allows for the rapid sequencing of entire genomes at a fraction of the cost of previous technologies, enabling comprehensive analysis and personalized treatment plans. NGS has revolutionized clinical diagnostics by facilitating the identification of genetic mutations linked to various diseases such as cancer, cardiovascular disorders, and rare genetic conditions. The versatility and high-throughput capabilities of NGS make it ideal for both clinical applications and research purposes, driving its widespread adoption in hospitals, research institutes, and pharmaceutical companies. As the technology continues to evolve, it is expected to further transform the genetic testing landscape by improving accuracy and reducing the time required for analysis.
Personalized Medicine Application Is Largest Due to Growing Demand for Tailored Treatments
Personalized medicine is the largest application within the genetic testing market. This approach, which uses genetic information to tailor medical treatment to individual patients, is gaining traction as it offers more precise and effective treatment options. The rise of pharmacogenomics, where genetic tests are used to determine the most effective drugs for a patient based on their genetic makeup, has made personalized medicine a key focus area in healthcare. The shift towards precision medicine is being driven by increasing investments in genetic research, advancements in technology, and the recognition of the benefits of targeted treatments in improving patient outcomes. As more healthcare providers adopt personalized medicine approaches, the demand for genetic testing is expected to continue growing.
Healthcare Providers End-User Industry Is Largest Owing to Increasing Adoption in Clinical Settings
Among the various end-user industries, healthcare providers are the largest segment in the genetic testing market. Hospitals, clinics, and diagnostic centers are leveraging genetic testing for disease diagnosis, carrier screening, and prenatal testing, among other applications. The rising demand for personalized medicine and the integration of genetic testing into routine clinical practices are the primary drivers behind this growth. Moreover, healthcare providers are increasingly adopting pharmacogenomic testing to optimize drug therapies and minimize adverse effects, further bolstering the demand for genetic testing services. The healthcare sector is expected to remain the dominant end-user industry, with hospitals and clinics playing a central role in the utilization of genetic tests for patient care.
North America Region Is Largest Market Owing to Advanced Healthcare Infrastructure and High Adoption Rates
North America is the largest regional market for genetic testing, primarily due to the well-established healthcare infrastructure, high levels of healthcare expenditure, and the widespread adoption of advanced genetic testing technologies. The United States, in particular, stands as a global leader in genetic testing adoption, driven by the prevalence of genetic testing services in clinical practice, strong consumer demand for direct-to-consumer testing, and the support of major players such as Illumina, 23andMe, and Thermo Fisher Scientific. Additionally, the regulatory environment in North America supports genetic testing innovations, further enhancing market growth. The region's dominance is expected to continue, although other regions such as Europe and Asia-Pacific are rapidly catching up.
Leading Companies and Competitive Landscape
The genetic testing market is highly competitive, with key players including Illumina, Thermo Fisher Scientific, Roche Diagnostics, 23andMe, and Ancestry.com. These companies dominate the market by offering a broad range of genetic testing services, from clinical diagnostics to direct-to-consumer products. As the market expands, companies are increasingly focusing on partnerships, acquisitions, and collaborations to enhance their product portfolios and expand their global reach. The competitive landscape is also shaped by ongoing technological advancements, particularly in next-generation sequencing (NGS) and CRISPR-based technologies. Furthermore, companies are investing heavily in research and development to create more accurate, faster, and cost-effective genetic testing solutions. As the demand for personalized medicine grows, these industry leaders are well-positioned to drive the next phase of growth in the genetic testing market.
Recent Developments:
- 23andMe announced a new partnership with a pharmaceutical company to develop personalized drug treatments based on genetic data.
- Illumina Inc. launched a new NGS platform aimed at improving genomic sequencing efficiency and reducing testing costs for clinical labs.
- Myriad Genetics acquired a genetic testing startup, expanding its portfolio of hereditary cancer risk assessment tools.
- Thermo Fisher Scientific received FDA approval for a new PCR-based genetic test to detect rare genetic diseases in newborns.
- Roche Diagnostics partnered with a leading research institution to develop a next-gen genetic testing system focused on rare genetic disorders
List of Leading Companies:
- 23andMe
- Ancestry.com
- Illumina Inc.
- Thermo Fisher Scientific
- Roche Diagnostics
- Myriad Genetics
- LabCorp
- Quest Diagnostics
- Fulgent Genetics
- Invitae Corporation
- BGI Group
- Gene by Gene
- Pacific Biosciences of California Inc.
- Eurofins Scientific
- Genetic Technologies
Report Scope:
|
Report Features |
Description |
|
Market Size (2024-e) |
USD 16.5 Billion |
|
Forecasted Value (2030) |
USD 44.2 Billion |
|
CAGR (2025 – 2030) |
15.2% |
|
Base Year for Estimation |
2024-e |
|
Historic Year |
2023 |
|
Forecast Period |
2025 – 2030 |
|
Report Coverage |
Market Forecast, Market Dynamics, Competitive Landscape, Recent Developments |
|
Segments Covered |
Genetic Testing Market By Product Type (Direct-to-Consumer Genetic Testing, Laboratory-Based Genetic Testing, Clinical Genetic Testing, Pharmacogenomic Testing), By Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Microarray, CRISPR-based Genetic Testing, Gene Chip Technology), By Application (Disease Diagnosis, Genetic Disorder Screening, Carrier Screening, Prenatal Genetic Testing, Personalized Medicine, Forensic Testing), By End-User Industry (Healthcare Providers, Pharmaceutical & Biotech Companies, Research Institutes, Direct-to-Consumer Services, Hospitals & Clinics) |
|
Regional Analysis |
North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, South Korea, Australia, India, and Rest of Asia-Pacific), Latin America (Brazil, Argentina, and Rest of Latin America), Middle East & Africa (Saudi Arabia, UAE, Rest of Middle East & Africa) |
|
Major Companies |
23andMe, Ancestry.com, Illumina Inc., Thermo Fisher Scientific, Roche Diagnostics, Myriad Genetics, LabCorp, Quest Diagnostics, Fulgent Genetics, Invitae Corporation, BGI Group, Gene by Gene, Pacific Biosciences of California Inc., Eurofins Scientific, Genetic Technologies |
|
Customization Scope |
Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements |
|
1. Introduction |
|
1.1. Market Definition |
|
1.2. Scope of the Study |
|
1.3. Research Assumptions |
|
1.4. Study Limitations |
|
2. Research Methodology |
|
2.1. Research Approach |
|
2.1.1. Top-Down Method |
|
2.1.2. Bottom-Up Method |
|
2.1.3. Factor Impact Analysis |
|
2.2. Insights & Data Collection Process |
|
2.2.1. Secondary Research |
|
2.2.2. Primary Research |
|
2.3. Data Mining Process |
|
2.3.1. Data Analysis |
|
2.3.2. Data Validation and Revalidation |
|
2.3.3. Data Triangulation |
|
3. Executive Summary |
|
3.1. Major Markets & Segments |
|
3.2. Highest Growing Regions and Respective Countries |
|
3.3. Impact of Growth Drivers & Inhibitors |
|
3.4. Regulatory Overview by Country |
|
4. Genetic Testing Market, by Product Type (Market Size & Forecast: USD Million, 2023 – 2030) |
|
4.1. Direct-to-Consumer Genetic Testing |
|
4.2. Laboratory-Based Genetic Testing |
|
4.3. Clinical Genetic Testing |
|
4.4. Pharmacogenomic Testing |
|
5. Genetic Testing Market, by Technology (Market Size & Forecast: USD Million, 2023 – 2030) |
|
5.1. Polymerase Chain Reaction (PCR) |
|
5.2. Next-Generation Sequencing (NGS) |
|
5.3. Microarray |
|
5.4. CRISPR-based Genetic Testing |
|
5.5. Gene Chip Technology |
|
6. Genetic Testing Market, by Application (Market Size & Forecast: USD Million, 2023 – 2030) |
|
6.1. Disease Diagnosis |
|
6.2. Genetic Disorder Screening |
|
6.3. Carrier Screening |
|
6.4. Prenatal Genetic Testing |
|
6.5. Personalized Medicine |
|
6.6. Forensic Testing |
|
7. Genetic Testing Market, by End-User Industry (Market Size & Forecast: USD Million, 2023 – 2030) |
|
7.1. Healthcare Providers |
|
7.2. Pharmaceutical & Biotech Companies |
|
7.3. Research Institutes |
|
7.4. Direct-to-Consumer Services |
|
7.5. Hospitals & Clinics |
|
8. Regional Analysis (Market Size & Forecast: USD Million, 2023 – 2030) |
|
8.1. Regional Overview |
|
8.2. North America |
|
8.2.1. Regional Trends & Growth Drivers |
|
8.2.2. Barriers & Challenges |
|
8.2.3. Opportunities |
|
8.2.4. Factor Impact Analysis |
|
8.2.5. Technology Trends |
|
8.2.6. North America Genetic Testing Market, by Product Type |
|
8.2.7. North America Genetic Testing Market, by Technology |
|
8.2.8. North America Genetic Testing Market, by Application |
|
8.2.9. North America Genetic Testing Market, by End-User Industry |
|
8.2.10. By Country |
|
8.2.10.1. US |
|
8.2.10.1.1. US Genetic Testing Market, by Product Type |
|
8.2.10.1.2. US Genetic Testing Market, by Technology |
|
8.2.10.1.3. US Genetic Testing Market, by Application |
|
8.2.10.1.4. US Genetic Testing Market, by End-User Industry |
|
8.2.10.2. Canada |
|
8.2.10.3. Mexico |
|
*Similar segmentation will be provided for each region and country |
|
8.3. Europe |
|
8.4. Asia-Pacific |
|
8.5. Latin America |
|
8.6. Middle East & Africa |
|
9. Competitive Landscape |
|
9.1. Overview of the Key Players |
|
9.2. Competitive Ecosystem |
|
9.2.1. Level of Fragmentation |
|
9.2.2. Market Consolidation |
|
9.2.3. Product Innovation |
|
9.3. Company Share Analysis |
|
9.4. Company Benchmarking Matrix |
|
9.4.1. Strategic Overview |
|
9.4.2. Product Innovations |
|
9.5. Start-up Ecosystem |
|
9.6. Strategic Competitive Insights/ Customer Imperatives |
|
9.7. ESG Matrix/ Sustainability Matrix |
|
9.8. Manufacturing Network |
|
9.8.1. Locations |
|
9.8.2. Supply Chain and Logistics |
|
9.8.3. Product Flexibility/Customization |
|
9.8.4. Digital Transformation and Connectivity |
|
9.8.5. Environmental and Regulatory Compliance |
|
9.9. Technology Readiness Level Matrix |
|
9.10. Technology Maturity Curve |
|
9.11. Buying Criteria |
|
10. Company Profiles |
|
10.1. 23andMe |
|
10.1.1. Company Overview |
|
10.1.2. Company Financials |
|
10.1.3. Product/Service Portfolio |
|
10.1.4. Recent Developments |
|
10.1.5. IMR Analysis |
|
*Similar information will be provided for other companies |
|
10.2. Ancestry.com |
|
10.3. Illumina Inc. |
|
10.4. Thermo Fisher Scientific |
|
10.5. Roche Diagnostics |
|
10.6. Myriad Genetics |
|
10.7. LabCorp |
|
10.8. Quest Diagnostics |
|
10.9. Fulgent Genetics |
|
10.10. Invitae Corporation |
|
10.11. BGI Group |
|
10.12. Gene by Gene |
|
10.13. Pacific Biosciences of California Inc. |
|
10.14. Eurofins Scientific |
|
10.15. Genetic Technologies |
|
11. Appendix |
A comprehensive market research approach was employed to gather and analyze data on the Genome Editing Market. In the process, the analysis was also done to analyze the parent market and relevant adjacencies to measure the impact of them on the Genome Editing Market. The research methodology encompassed both secondary and primary research techniques, ensuring the accuracy and credibility of the findings.
.jpg)
Secondary Research
Secondary research involved a thorough review of pertinent industry reports, journals, articles, and publications. Additionally, annual reports, press releases, and investor presentations of industry players were scrutinized to gain insights into their market positioning and strategies.
Primary Research
Primary research involved conducting in-depth interviews with industry experts, stakeholders, and market participants across the E-Waste Management ecosystem. The primary research objectives included:
- Validating findings and assumptions derived from secondary research
- Gathering qualitative and quantitative data on market trends, drivers, and challenges
- Understanding the demand-side dynamics, encompassing end-users, component manufacturers, facility providers, and service providers
- Assessing the supply-side landscape, including technological advancements and recent developments
Market Size Assessment
A combination of top-down and bottom-up approaches was utilized to analyze the overall size of the Genome Editing Market. These methods were also employed to assess the size of various subsegments within the market. The market size assessment methodology encompassed the following steps:
- Identification of key industry players and relevant revenues through extensive secondary research
- Determination of the industry's supply chain and market size, in terms of value, through primary and secondary research processes
- Calculation of percentage shares, splits, and breakdowns using secondary sources and verification through primary sources
.jpg)
Data Triangulation
To ensure the accuracy and reliability of the market size, data triangulation was implemented. This involved cross-referencing data from various sources, including demand and supply side factors, market trends, and expert opinions. Additionally, top-down and bottom-up approaches were employed to validate the market size assessment.
ensuring the accuracy and credibility of the findings.
Secondary Research
Secondary research involved a thorough review of pertinent industry reports, journals, articles, and publications. Additionally, annual reports, press releases, and investor presentations of industry players were scrutinized to gain insights into their market positioning and strategies.
Primary Research
Primary research involved conducting in-depth interviews with industry experts, stakeholders, and market participants across the E-Waste Management ecosystem. The primary research objectives included:
- Validating findings and assumptions derived from secondary research
- Gathering qualitative and quantitative data on market trends, drivers, and challenges
- Understanding the demand-side dynamics, encompassing end-users, component manufacturers, facility providers, and service providers
- Assessing the supply-side landscape, including technological advancements and recent developments
Market Size Assessment
A combination of top-down and bottom-up approaches was utilized to analyze the overall size of the Genetic Testing Market. These methods were also employed to assess the size of various subsegments within the market. The market size assessment methodology encompassed the following steps:
- Identification of key industry players and relevant revenues through extensive secondary research
- Determination of the industry's supply chain and market size, in terms of value, through primary and secondary research processes
- Calculation of percentage shares, splits, and breakdowns using secondary sources and verification through primary sources
Data Triangulation
To ensure the accuracy and reliability of the market size, data triangulation was implemented. This involved cross-referencing data from various sources, including demand and supply side factors, market trends, and expert opinions. Additionally, top-down and bottom-up approaches were employed to validate the market size assessment.
NA